Improving quality of life in multiple sclerosis

Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms of limbs and torso. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, and improve the lives of people with this serious and incurable disorder.

The company’s lead compound, VSN16R, has completed Phase I human safety trials, with excellent results.

Investors in Canbex include MS Ventures, the corporate venture arm of Merck KGaA; the Wellcome Trust; "Fast Forward", the drug development arm of the US National Multiple Sclerosis Society; University College London (UCL Business PLC); and Esperante Ventures.

Our goal is to improve the quality of life for people with multiple sclerosis though better treatment of spasticity.